Oncology Views & Analysis

Views & Analysis

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers.

Views & Analysis

Dreaming big with small molecules

Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade.

Oncology

approximate the DNA molecule on a blue background

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.

Views & Analysis

How the NHS got ahead of the curve with CAR-T

The UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies.

Views & Analysis

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Merck KGaA's bold new approach to cancer immunotherapy

Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.

Views & Analysis

Doctor Checking Skin Of Patient With Magnifying Glass

Quality of life increasingly important in skin cancer, say d...

The factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved a major talking point at an event on the fringes of this year’s ESMO conference

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Dreaming big with small molecules

Has the NHS joined the biosimilars revolution?

How the NHS got ahead of the curve with CAR-T

Merck KGaA's bold new approach to cancer immunotherapy

Quality of life increasingly important in skin cancer, say d...

Vaxcyte's pneumococcal jab exceeds expectations

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks